Merus NV (FRA:2GH)
€ 52.5 3.9 (8.02%) Market Cap: 3.31 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 8.94 GF Score: 51/100

Merus NV at Needham Healthcare Conference (Virtual) Transcript

Apr 13, 2022 / 02:15PM GMT
Release Date Price: €22 (-4.35%)
Ami Fadia
Needham & Company - Analyst

Good morning, everyone, again. This is Ami Fadia; I cover neuroscience and targeted oncology at Needham. It's my pleasure to be hosting Merus for this next session, and we have with us Bill Lundberg who is the CEO of the company. (Conference Instructions) And with that let me kick it off.

Questions & Answers

Ami Fadia
Needham & Company - Analyst

Bill, Zeno is top of mind for everybody listening in. So, perhaps if you could start by giving us an update on where things stand with the Phase 1/2 trial. You're due to expect some data in the near future.

Bill Lundberg
Merus NV - President, CEO, Principal Financial Officer & Executive Director

Happy to. And first let me say thank you to you and the entire Needham team and to the support staff for allowing us to participate. We really appreciate the opportunity to share where we are and progress to date. And also just a couple words about the company.

As many of you know, but perhaps not all, we're a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot